Author:
Bhagwat Ajay,Doke Rohit Doke,Ghule Santosh,Gandhi Bipin
Abstract
Acute myeloid leukaemia is becoming more predominant in blood cancer in geriatrics people groups. In 2017, four new therapeutic candidates have been approved by the FDA: Enasidenib, CPX 351, Midostaurin, and Gemtuzumab ozogamicin; with the approval of Venetoclax and Daurismo, additional advances were achieved in 2018. Ivosidenib and gilteritinib were also accepted as single-agent therapy in persistent and recurrent AML 2018. Most of the anticancer drugs belong to Biopharmaceutical classification system-II (BSC), and BCS class-IV has poor bioavailability because of solubility issues. We will overcome this problem by preparing nanoparticles of this drug by using different nanoparticle preparation methods.
Publisher
BSP Books Private Limited
Subject
Pharmacology (medical),Clinical Biochemistry,General Pharmacology, Toxicology and Pharmaceutics,Pharmacy
Reference76 articles.
1. Lagunas-Rangel, F. A., Chávez-Valencia, V., Gómez-Guijosa, M. Á. & Cortes-Penagos, C. Acute myeloid leukemia—genetic alterations and their clinical prognosis. Int. J. Hematol. Stem Cell Res. 2017; 11, 329–339.
2. Rubio-Jurado, B. et al. New biomarkers in non-Hodgkin lymphoma and acute leukemias. Advances in Clinical Chemistry vol. 96 (Elsevier Inc., 2020.
3. Yao, Y., Lin, X., Li, F., Jin, J. & Wang, H. The global burden and attributable risk factors of chronic lymphocytic leukemia in 204 countries and territories from 1990 to 2019: analysis based on the global burden of disease study 2019. Biomed. Eng. Online 2022; 21, 1–16.
4. Dong, Y. et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp. Hematol. Oncol. 2020; 9, 1–11.
5. Lai, C., Doucette, K. & Norsworthy, K. Recent drug approvals for acute myeloid leukemia. J. Hematol. Oncol. 2019; 12, 1–20 .